Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

A multisubstrate adduct inhibitor of a purine biosynthetic enzyme with a picomolar dissociation constant.

Inglese J, Blatchly RA, Benkovic SJ.

J Med Chem. 1989 May;32(5):937-40. No abstract available. Erratum in: J Med Chem 1989 Dec;32(12):2583.

PMID:
2709379
2.

A multisubstrate adduct inhibitor of AICAR transformylase.

Wall M, Shim JH, Benkovic SJ.

J Med Chem. 1999 Sep 9;42(18):3421-4. No abstract available.

PMID:
10479275
3.
4.

Design, synthesis, and biological evaluation of fluoronitrophenyl substituted folate analogues as potential inhibitors of GAR transformylase and AICAR transformylase.

Boger DL, Marsilje TH, Castro RA, Hedrick MP, Jin Q, Baker SJ, Shim JH, Benkovic SJ.

Bioorg Med Chem Lett. 2000 Jul 3;10(13):1471-5.

PMID:
10888335
5.

10-Formyl-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid (10-formyl-DDACTHF): a potent cytotoxic agent acting by selective inhibition of human GAR Tfase and the de novo purine biosynthetic pathway.

Marsilje TH, Labroli MA, Hedrick MP, Jin Q, Desharnais J, Baker SJ, Gooljarsingh LT, Ramcharan J, Tavassoli A, Zhang Y, Wilson IA, Beardsley GP, Benkovic SJ, Boger DL.

Bioorg Med Chem. 2002 Aug;10(8):2739-49.

PMID:
12057663
6.

Unexpected formation of an epoxide-derived multisubstrate adduct inhibitor on the active site of GAR transformylase.

Greasley SE, Marsilje TH, Cai H, Baker S, Benkovic SJ, Boger DL, Wilson IA.

Biochemistry. 2001 Nov 13;40(45):13538-47.

PMID:
11695901
9.
10.

Direct transfer of one-carbon units in the transformylations of de novo purine biosynthesis.

Smith GK, Mueller WT, Slieker LJ, DeBrosse CW, Benkovic SJ.

Biochemistry. 1982 Jun 8;21(12):2870-4.

PMID:
7104299
11.

Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol.

Mendelsohn LG, Shih C, Schultz RM, Worzalla JF.

Invest New Drugs. 1996;14(3):287-94.

PMID:
8958184
12.
13.
14.

Assignment of a third purine biosynthetic gene (glycinamide ribonucleotide transformylase) to human chromosome 21.

Hards RG, Benkovic SJ, Van Keuren ML, Graw SL, Drabkin HA, Patterson D.

Am J Hum Genet. 1986 Aug;39(2):179-85.

15.

10-(2-benzoxazolcarbonyl)-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid: a potential inhibitor of GAR transformylase and AICAR transformylase.

Marsilje TH, Hedrick MP, Desharnais J, Capps K, Tavassoli A, Zhang Y, Wilson IA, Benkovic SJ, Boger DL.

Bioorg Med Chem. 2003 Oct 1;11(20):4503-9.

PMID:
13129586
16.

Design, synthesis and biological evaluation of 10-CF3CO-DDACTHF analogues and derivatives as inhibitors of GAR Tfase and the de novo purine biosynthetic pathway.

Desharnais J, Hwang I, Zhang Y, Tavassoli A, Baboval J, Benkovic SJ, Wilson IA, Boger DL.

Bioorg Med Chem. 2003 Oct 1;11(20):4511-21.

PMID:
13129587
17.

Newer antifolates in cancer therapy.

Schultz RM.

Prog Drug Res. 1995;44:129-57. Review. No abstract available.

PMID:
7644664
18.

A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors.

Habeck LL, Leitner TA, Shackelford KA, Gossett LS, Schultz RM, Andis SL, Shih C, Grindey GB, Mendelsohn LG.

Cancer Res. 1994 Feb 15;54(4):1021-6.

PMID:
8313357
19.

Design, synthesis, and evaluation of potential GAR and AICAR transformylase inhibitors.

Boger DL, Kochanny MJ, Cai H, Wyatt D, Kitos PA, Warren MS, Ramcharan J, Gooljarsingh LT, Benkovic SJ.

Bioorg Med Chem. 1998 Jun;6(6):643-59. No abstract available.

PMID:
9681131
20.

Synthesis and biological evaluation of alpha- and gamma-carboxamide derivatives of 10-CF3CO-DDACTHF.

Chong Y, Hwang I, Tavassoli A, Zhang Y, Wilson IA, Benkovic SJ, Boger DL.

Bioorg Med Chem. 2005 May 16;13(10):3587-92.

PMID:
15848771
Items per page

Supplemental Content

Write to the Help Desk